




RealRate

PHARMACEUTICAL 2021

Clovis Oncology Inc.
Rank 278 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Clovis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Clovis Oncology Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Clovis Oncology Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 122% points.

The company's Economic Capital Ratio, given in the ranking table, is -244%, being 111% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	310,829
Cost of Goods Sold	0
Intangible Assets	128,817
Liabilities, Current	184,928
Liabilities, Non-Current	0
Other Assets	153,823
Other Compr. Net Income	561
Other Expenses	44,562
Other Liabilities	579,374
Other Net Income	-67,571
Property and Equipment	12,085
Research and Development	257,707
Revenues	164,522
Selling, General and Administrative Expense	163,894

Output Variable	Value in 1000 USD
Assets	605,554
Liabilities	764,302
Expenses	466,163
Stockholders Equity	-158,748
Net Income	-369,212
Comprehensive Net Income	-368,932
Economic Capital Ratio	-244%